RadNet (RDNT) Competitors $57.14 -0.80 (-1.38%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$57.53 +0.39 (+0.68%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RDNT vs. HIMS, GH, OPCH, BTSG, SHC, SGRY, CON, PRVA, WGS, and VCYTShould you be buying RadNet stock or one of its competitors? The main competitors of RadNet include Hims & Hers Health (HIMS), Guardant Health (GH), Option Care Health (OPCH), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), GeneDx (WGS), and Veracyte (VCYT). These companies are all part of the "healthcare" industry. RadNet vs. Its Competitors Hims & Hers Health Guardant Health Option Care Health BrightSpring Health Services Sotera Health Surgery Partners Concentra Group Holdings Parent Privia Health Group GeneDx Veracyte RadNet (NASDAQ:RDNT) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk. Do insiders & institutionals hold more shares of RDNT or HIMS? 77.9% of RadNet shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 5.6% of RadNet shares are owned by company insiders. Comparatively, 17.7% of Hims & Hers Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, RDNT or HIMS? Hims & Hers Health has lower revenue, but higher earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRadNet$1.83B2.34$2.79M-$0.43-132.88Hims & Hers Health$1.78B6.26$126.04M$0.6972.36 Do analysts prefer RDNT or HIMS? RadNet currently has a consensus target price of $69.60, suggesting a potential upside of 21.81%. Hims & Hers Health has a consensus target price of $39.83, suggesting a potential downside of 20.22%. Given RadNet's stronger consensus rating and higher probable upside, analysts clearly believe RadNet is more favorable than Hims & Hers Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RadNet 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 3 Strong Buy rating(s) 3.50Hims & Hers Health 3 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.92 Does the media prefer RDNT or HIMS? In the previous week, Hims & Hers Health had 62 more articles in the media than RadNet. MarketBeat recorded 71 mentions for Hims & Hers Health and 9 mentions for RadNet. RadNet's average media sentiment score of 1.31 beat Hims & Hers Health's score of 0.37 indicating that RadNet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 15 Very Positive mention(s) 8 Positive mention(s) 41 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more risk & volatility, RDNT or HIMS? RadNet has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500. Is RDNT or HIMS more profitable? Hims & Hers Health has a net margin of 9.24% compared to RadNet's net margin of -1.73%. Hims & Hers Health's return on equity of 22.75% beat RadNet's return on equity.Company Net Margins Return on Equity Return on Assets RadNet-1.73% 1.41% 0.48% Hims & Hers Health 9.24%22.75%15.51% SummaryHims & Hers Health beats RadNet on 10 of the 17 factors compared between the two stocks. Get RadNet News Delivered to You Automatically Sign up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDNT vs. The Competition Export to ExcelMetricRadNetMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.35B$3.74B$5.48B$9.44BDividend YieldN/A1.36%4.01%4.02%P/E Ratio-132.8834.9828.3619.90Price / Sales2.34122.45415.0786.48Price / Cash16.6421.9635.9658.29Price / Book3.734.418.365.67Net Income$2.79M$189.47M$3.24B$258.18M7 Day Performance-0.21%2.06%3.13%2.81%1 Month Performance4.14%-3.16%10.98%13.53%1 Year Performance-12.16%-3.20%34.48%17.68% RadNet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDNTRadNet3.7698 of 5 stars$57.14-1.4%$69.60+21.8%-8.8%$4.35B$1.83B-132.8811,021HIMSHims & Hers Health2.523 of 5 stars$51.98+8.5%$39.58-23.8%+145.5%$11.63B$1.48B75.331,637Trending NewsAnalyst UpgradeGHGuardant Health4.4908 of 5 stars$49.77-1.0%$53.76+8.0%+44.5%$6.17B$739.02M-14.682,021Upcoming EarningsAnalyst RevisionOPCHOption Care Health4.5389 of 5 stars$30.68+2.7%$35.50+15.7%-4.4%$5.02B$5.00B24.748,088Positive NewsUpcoming EarningsBTSGBrightSpring Health Services1.9874 of 5 stars$20.31flat$24.90+22.6%+68.5%$3.57B$11.86B72.5435,000SHCSotera Health3.2778 of 5 stars$11.61-1.6%$16.00+37.8%-13.5%$3.30B$1.10B145.143,000Positive NewsSGRYSurgery Partners2.861 of 5 stars$22.47+2.0%$33.56+49.3%-21.7%$2.88B$3.11B-14.6915,000CONConcentra Group Holdings Parent3.0177 of 5 stars$20.23+1.6%$28.50+40.9%N/A$2.59B$1.90B15.0911,250PRVAPrivia Health Group4.1044 of 5 stars$20.89+2.1%$28.38+35.9%+2.3%$2.55B$1.80B174.101,140Positive NewsWGSGeneDx3.952 of 5 stars$82.39-0.2%$92.33+12.1%+148.8%$2.35B$330.14M-58.431,200Upcoming EarningsVCYTVeracyte3.6826 of 5 stars$26.65-1.6%$40.90+53.5%+0.2%$2.09B$445.76M65.00790 Related Companies and Tools Related Companies Hims & Hers Health Alternatives Guardant Health Alternatives Option Care Health Alternatives BrightSpring Health Services Alternatives Sotera Health Alternatives Surgery Partners Alternatives Concentra Group Holdings Parent Alternatives Privia Health Group Alternatives GeneDx Alternatives Veracyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDNT) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RadNet, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RadNet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDNT Stock Alerts